We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · October 04, 2022

Patient-Reported QoL in Patients With HR+/HER2− Advanced Breast Cancer Treated With Palbociclib Plus Letrozole

Annals of Oncology

 

Additional Info

Annals of Oncology
218P Patient-reported quality of life in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) treated with palbociclib (PAL) plus letrozole (LET): Results from PALOMA-4
Ann. Oncol 2022 Sep 01;33(suppl 7)S637, X Hu, E Broughton, W Li, et al

Further Reading